Experimental cancer drug PTX-100 enters early human testing
NCT ID NCT03900442
First seen Jun 26, 2026 · Last updated Jun 26, 2026
Summary
This early-phase trial tested a new drug called PTX-100 in 25 people with advanced cancers like multiple myeloma, lymphoma, and certain solid tumors. The goal was to find safe doses and understand how the drug behaves in the body. Participants received the drug by IV for five days every two weeks, for up to four cycles.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- PTX-100
- What this could lead to
- If successful, this could point toward a new treatment option for certain advanced cancers that have not responded to standard therapies.
- What could go wrong
- This is a very early Phase 1 trial with only 25 participants, so it is too small to prove effectiveness. The drug may not work or could cause significant side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Epworth Healthcare
Melbourne, Victoria, 3002, Australia
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a plasma beam stop colon polyps from coming back?
- A stitch in time: could a device make abdominal closure safer?
- Could muscle loss predict blood cancer outcomes?
- Can a Triple-Action antibody deepen remissions in myeloma?
- Can we predict chemo brain before it happens?
- Your gut bacteria might reveal hidden cancer risk